Page 3 - Admission Document News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Proposed Secondary Placing of Existing Shares | Company Announcement

Investegate announcements from Proposed Secondary Placing of Existing Shares

United kingdomUnited statesCity ofDistrict of columbiaRob weiszMichael foulkesRobert weiszWilliam nealeRichard thompsonFinancial conduct authorityCompany the placingCavendish capital markets limitedPdmrs of the companyConcert partyGiven the companyCommission delegated directive

On Market Share Buyback Programme | Company Announcement

Investegate announcements from On Market Share Buyback Programme

United kingdomJonny franklin adams seamus frickerWilliam nealeRobert weiszRichard thompsonCarmel warrenEdward spurrierMichael foulkesShare buyback programmeCompany ordinaryCavendish capital markets limited nomadMarket share buyback programmeCompany nominated adviserCommission delegated regulationConcert partyCompany admission document

Proposed Placing to raise approximately £1 million | Company Announcement

Proposed Placing to raise approximately £1 million | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

South africaNorthern irelandUnited kingdomWestern australiaUnited statesNew zealandCity ofRepublic of south africaSouth africanBeaumont cornishNeither the companyCompany for the placingCompany nominated adviserFinancial servicesInvestments commissionOffice of foreign assets

Proposed equity fundraising | Company Announcement

Investegate announcements from Proposed equity fundraising

Northern irelandUnited kingdomCity ofNew zealandSouth africaUnited statesRepublic of south africaSouth africanCompanyor windarOffice of foreign assetsWh irelandRegulatory information serviceFinancial servicesEuroclear united kingdom internationalHill capitalEuropean parliament

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp after single and multiple dosing .

United statesCurtis rambaranHansoh pharmaJournal of the american medical associationExchange commission onSilence therapeuticsAmerican medical associationChief medical officerSecurities litigation reform actAdmission documentAnnual reportExchange commission